Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

ABSTRACT:

Background

Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice.

Methods

A two-center, open-label study of intermittent DQ (D:100 mg/day, Q:1250 mg/day, three-days/week over three-weeks) was conducted in participants with IPF (n = 14) to evaluate feasibility of implementing a senolytic intervention. The primary endpoints were retention rates and completion rates for planned clinical assessments. Secondary endpoints were safety and change in functional and reported hea

SUBMITTER: Justice JN 

PROVIDER: S-EPMC6412088 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature